This is a Validated Antibody Database (VAD) review about rat Cdk6, based on 40 published articles (read how Labome selects the articles), using Cdk6 antibody in all methods. It is aimed to help Labome visitors find the most suited Cdk6 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Knockout validation
Invitrogen
mouse monoclonal (K6.83 (DCS-83))
  • western blot knockout validation; mouse; 1:1000; loading ...; fig s17
Invitrogen Cdk6 antibody (Thermo, AHZ0232) was used in western blot knockout validation on mouse samples at 1:1000 (fig s17). Nat Commun (2019) ncbi
Cell Signaling Technology
mouse monoclonal (DCS83)
  • western blot knockout validation; mouse; loading ...; fig s2h
  • western blot; human; loading ...; fig s2i
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot knockout validation on mouse samples (fig s2h) and in western blot on human samples (fig s2i). Nature (2018) ncbi
Santa Cruz Biotechnology
mouse monoclonal (B-10)
  • western blot; human; 1:1000; loading ...; fig 13
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc-7961) was used in western blot on human samples at 1:1000 (fig 13). Int J Oncol (2022) ncbi
mouse monoclonal (B-10)
  • western blot; human; loading ...; fig 3f
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc-7961) was used in western blot on human samples (fig 3f). Mol Cancer (2020) ncbi
mouse monoclonal (B-10)
  • western blot; human; loading ...; fig 5g
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc-7961) was used in western blot on human samples (fig 5g). J Exp Clin Cancer Res (2019) ncbi
mouse monoclonal (B-10)
  • western blot; human; loading ...; fig 2c
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc-7961) was used in western blot on human samples (fig 2c). Cell Rep (2019) ncbi
mouse monoclonal
  • western blot; human; fig 1g
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, B?\10) was used in western blot on human samples (fig 1g). EMBO J (2017) ncbi
mouse monoclonal (B-10)
  • western blot; human; fig 1g
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, B?\10) was used in western blot on human samples (fig 1g). EMBO J (2017) ncbi
mouse monoclonal (B-10)
  • western blot; human; 1:500; loading ...; fig 5h
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc-7961) was used in western blot on human samples at 1:500 (fig 5h). Nat Commun (2017) ncbi
mouse monoclonal (SPM383)
  • western blot; rat; 1:1000; loading ...; fig 4e
In order to present the role of CDK6 in miR-1, Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc-56362) was used in western blot on rat samples at 1:1000 (fig 4e). Mol Cell Biochem (2016) ncbi
mouse monoclonal (DCS-83)
  • western blot; rat; 1:500; fig 3
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, SC53638) was used in western blot on rat samples at 1:500 (fig 3). Int J Mol Med (2015) ncbi
mouse monoclonal (B-10)
  • immunocytochemistry; human; fig 3
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc7961) was used in immunocytochemistry on human samples (fig 3). Cell Stem Cell (2015) ncbi
mouse monoclonal (B-10)
  • immunohistochemistry; African green monkey; 1:400
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz Biotechnology, SC-7961) was used in immunohistochemistry on African green monkey samples at 1:400. Endocrinology (2014) ncbi
mouse monoclonal (B-10)
  • western blot; human; fig 3
Santa Cruz Biotechnology Cdk6 antibody (Santa Cruz, sc-7961) was used in western blot on human samples (fig 3). Clin Cancer Res (2010) ncbi
Invitrogen
mouse monoclonal (K6.83 (DCS-83))
  • western blot knockout validation; mouse; 1:1000; loading ...; fig s17
Invitrogen Cdk6 antibody (Thermo, AHZ0232) was used in western blot knockout validation on mouse samples at 1:1000 (fig s17). Nat Commun (2019) ncbi
Cell Signaling Technology
mouse monoclonal (DCS83)
  • western blot; mouse; 1:1000; loading ...; fig 5a, 5f
Cell Signaling Technology Cdk6 antibody (CST, 3136T) was used in western blot on mouse samples at 1:1000 (fig 5a, 5f). Aging Cell (2021) ncbi
mouse monoclonal (DCS83)
  • western blot; human; 1:1000; loading ...; fig 3b
Cell Signaling Technology Cdk6 antibody (Cell Signaling Technology, 3136) was used in western blot on human samples at 1:1000 (fig 3b). Clin Transl Med (2021) ncbi
mouse monoclonal (DCS83)
  • western blot; rat; 1:1000; fig 6a
Cell Signaling Technology Cdk6 antibody (CST, 3136T) was used in western blot on rat samples at 1:1000 (fig 6a). Am J Cancer Res (2021) ncbi
mouse monoclonal (DCS83)
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used . Protein Expr Purif (2021) ncbi
mouse monoclonal (DCS83)
  • western blot; mouse; loading ...; fig 4d
Cell Signaling Technology Cdk6 antibody (Sigma, 3136) was used in western blot on mouse samples (fig 4d). Cell Rep (2019) ncbi
mouse monoclonal (DCS83)
  • western blot; human; loading ...; fig 4e
Cell Signaling Technology Cdk6 antibody (Cell Signaling Technology, 3136) was used in western blot on human samples (fig 4e). Cancer Lett (2019) ncbi
mouse monoclonal (DCS83)
  • western blot knockout validation; mouse; loading ...; fig s2h
  • western blot; human; loading ...; fig s2i
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot knockout validation on mouse samples (fig s2h) and in western blot on human samples (fig s2i). Nature (2018) ncbi
mouse monoclonal (DCS83)
  • western blot; human; loading ...; fig 2g
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 2g). Oncogene (2017) ncbi
mouse monoclonal (DCS83)
  • western blot; human; loading ...; fig s1c
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig s1c). Nature (2017) ncbi
mouse monoclonal (DCS83)
  • western blot; human; loading ...; fig 2c
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 2c). J Biol Chem (2017) ncbi
mouse monoclonal (DCS83)
  • western blot; human; 1:500; loading ...; fig 2b
Cell Signaling Technology Cdk6 antibody (Cell signaling, 3136) was used in western blot on human samples at 1:500 (fig 2b). Cell Cycle (2017) ncbi
mouse monoclonal (DCS83)
  • western blot; human; 1:1000; loading ...; fig s5a
In order to identify and characterize an inhibitor of the COP9 signalosome, Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples at 1:1000 (fig s5a). Nat Commun (2016) ncbi
mouse monoclonal (DCS83)
  • western blot; human; 1:1000; loading ...; fig s3b
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples at 1:1000 (fig s3b). Oncogene (2017) ncbi
mouse monoclonal (DCS83)
  • western blot; human; loading ...; fig 3c
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 3c). J Exp Clin Cancer Res (2016) ncbi
mouse monoclonal (DCS83)
  • western blot; mouse; fig 1
In order to characterize an essential insulin effector in adipocytes called CDK4, Cell Signaling Technology Cdk6 antibody (Cell Signaling Technology, DCS83) was used in western blot on mouse samples (fig 1). J Clin Invest (2016) ncbi
mouse monoclonal (DCS83)
  • western blot; human; fig 4
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 4). Cell Cycle (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; human; fig 3d
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 3d). PLoS ONE (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; human; fig 4
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 4). Drug Des Devel Ther (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; human; 1:2000; loading ...; fig 4a
Cell Signaling Technology Cdk6 antibody (Cell Signaling Technology, DCS83) was used in western blot on human samples at 1:2000 (fig 4a). PLoS ONE (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; human; fig 4
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 4). PLoS ONE (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; mouse; loading ...; fig 1,2
  • western blot; human; loading ...; fig 1,2
Cell Signaling Technology Cdk6 antibody (Cell Signaling Technology Inc., 3136S) was used in western blot on mouse samples (fig 1,2) and in western blot on human samples (fig 1,2). Oncogene (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; human; fig 1
Cell Signaling Technology Cdk6 antibody (Cell Signaling Technology, 3136) was used in western blot on human samples (fig 1). J Biol Chem (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; human; fig 5
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 5). J Cell Physiol (2015) ncbi
mouse monoclonal (DCS83)
  • western blot; human; loading ...; fig 6e
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples (fig 6e). Mol Endocrinol (2014) ncbi
mouse monoclonal (DCS83)
  • western blot; human
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples . Cell Cycle (2014) ncbi
mouse monoclonal (DCS83)
  • western blot; human; 1:500
Cell Signaling Technology Cdk6 antibody (Cell Signaling, 3136) was used in western blot on human samples at 1:500. PPAR Res (2014) ncbi
MilliporeSigma
domestic rabbit polyclonal
  • western blot; mouse; loading ...; fig 2i
MilliporeSigma Cdk6 antibody (Sigma-Aldrich, HPA002637) was used in western blot on mouse samples (fig 2i). Life Sci Alliance (2021) ncbi
domestic rabbit polyclonal
  • chromatin immunoprecipitation; human; loading ...; fig 4f
MilliporeSigma Cdk6 antibody (MilliporeSigma, HPA002637) was used in chromatin immunoprecipitation on human samples (fig 4f). J Clin Invest (2020) ncbi
Articles Reviewed
  1. Geng F, Yang W, Song D, Hou H, Han B, Chen Y, et al. MDIG, a 2‑oxoglutarate‑dependent oxygenase, acts as an oncogene and predicts the prognosis of multiple types of cancer. Int J Oncol. 2022;61: pubmed publisher
  2. Xu X, Shen X, Wang J, Feng W, Wang M, Miao X, et al. YAP prevents premature senescence of astrocytes and cognitive decline of Alzheimer's disease through regulating CDK6 signaling. Aging Cell. 2021;20:e13465 pubmed publisher
  3. Sakai H, Kawakami H, Teramura T, Onodera Y, Somers E, Furuuchi K, et al. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. Clin Transl Med. 2021;11:e454 pubmed publisher
  4. Yang D, Xu X, Wang X, Feng W, Shen X, Zhang J, et al. β-elemene promotes the senescence of glioma cells through regulating YAP-CDK6 signaling. Am J Cancer Res. 2021;11:370-388 pubmed
  5. Redl E, Sheibani Tezerji R, Cardona C, Hamminger P, Timelthaler G, Hassler M, et al. Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis. Life Sci Alliance. 2021;4: pubmed publisher
  6. Abdel Aziz M, Fan Y, Liu L, Moasser M, Fu H, Jura N, et al. Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein Expr Purif. 2021;179:105780 pubmed publisher
  7. Muller A, Dickmanns A, Resch C, Schakel K, Hailfinger S, Dobbelstein M, et al. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. J Clin Invest. 2020;: pubmed publisher
  8. Lu C, Wei Y, Wang X, Zhang Z, Yin J, Li W, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19:28 pubmed publisher
  9. Si J, Ma Y, Bi J, Xiong Y, Lv C, Li S, et al. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties. J Exp Clin Cancer Res. 2019;38:481 pubmed publisher
  10. Krimpenfort P, Snoek M, Lambooij J, Song J, van der Weide R, Bhaskaran R, et al. A natural WNT signaling variant potently synergizes with Cdkn2ab loss in skin carcinogenesis. Nat Commun. 2019;10:1425 pubmed publisher
  11. Cornell L, Wander S, Visal T, Wagle N, Shapiro G. MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Rep. 2019;26:2667-2680.e7 pubmed publisher
  12. Lin K, Qiang W, Zhu M, Ding Y, Shi Q, Chen X, et al. Mammalian Pum1 and Pum2 Control Body Size via Translational Regulation of the Cell Cycle Inhibitor Cdkn1b. Cell Rep. 2019;26:2434-2450.e6 pubmed publisher
  13. Song X, Chen H, Zhang C, Yu Y, Chen Z, Liang H, et al. SRC-3 inhibition blocks tumor growth of pancreatic ductal adenocarcinoma. Cancer Lett. 2019;442:310-319 pubmed publisher
  14. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira N, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91-95 pubmed publisher
  15. Zhou Y, Huang T, Zhang J, Wong C, Zhang B, Dong Y, et al. TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene. 2017;36:6518-6530 pubmed publisher
  16. Wang H, Nicolay B, Chick J, Gao X, Geng Y, Ren H, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017;546:426-430 pubmed publisher
  17. Juhasz A, Markel S, Gaur S, Liu H, Lu J, Jiang G, et al. NADPH oxidase 1 supports proliferation of colon cancer cells by modulating reactive oxygen species-dependent signal transduction. J Biol Chem. 2017;292:7866-7887 pubmed publisher
  18. Mlcochova P, Sutherland K, Watters S, Bertoli C, de Bruin R, Rehwinkel J, et al. A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. EMBO J. 2017;36:604-616 pubmed publisher
  19. Liu T, Yu J, Deng M, Yin Y, Zhang H, Luo K, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun. 2017;8:13923 pubmed publisher
  20. Nuzzo A, Giuffrida D, Masturzo B, Mele P, Piccoli E, Eva C, et al. Altered expression of G1/S phase cell cycle regulators in placental mesenchymal stromal cells derived from preeclamptic pregnancies with fetal-placental compromise. Cell Cycle. 2017;16:200-212 pubmed publisher
  21. Schlierf A, Altmann E, Quancard J, Jefferson A, Assenberg R, Renatus M, et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016;7:13166 pubmed publisher
  22. Queisser A, Hagedorn S, Wang H, Schaefer T, Konantz M, Alavi S, et al. Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene. 2017;36:1573-1584 pubmed publisher
  23. Li J, Tang C, Li L, Li R, Fan Y. Quercetin sensitizes glioblastoma to t-AUCB by dual inhibition of Hsp27 and COX-2 in vitro and in vivo. J Exp Clin Cancer Res. 2016;35:61 pubmed publisher
  24. Yuan W, Tang C, Zhu W, Zhu J, Lin Q, Fu Y, et al. CDK6 mediates the effect of attenuation of miR-1 on provoking cardiomyocyte hypertrophy. Mol Cell Biochem. 2016;412:289-96 pubmed publisher
  25. Lagarrigue S, Lopez Mejia I, Denechaud P, Escoté X, Castillo Armengol J, Jimenez V, et al. CDK4 is an essential insulin effector in adipocytes. J Clin Invest. 2016;126:335-48 pubmed publisher
  26. Adam M, Matt S, Christian S, Hess Stumpp H, Haegebarth A, Hofmann T, et al. SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status. Cell Cycle. 2015;14:3734-47 pubmed publisher
  27. Kim Y, Chen C, Bolton E. Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells. PLoS ONE. 2015;10:e0138286 pubmed publisher
  28. Chiang K, Chen H, Hsu S, Pang J, Wang S, Hsu J, et al. PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. Drug Des Devel Ther. 2015;9:4631-8 pubmed publisher
  29. Yan G, Wang Q, Hu S, Wang D, Qiao Y, Ma G, et al. Digoxin inhibits PDGF-BB-induced VSMC proliferation and migration through an increase in ILK signaling and attenuates neointima formation following carotid injury. Int J Mol Med. 2015;36:1001-11 pubmed publisher
  30. Marzagalli M, Casati L, Moretti R, Montagnani Marelli M, Limonta P. Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS ONE. 2015;10:e0134396 pubmed publisher
  31. Navarro F, Lieberman J. miR-34 and p53: New Insights into a Complex Functional Relationship. PLoS ONE. 2015;10:e0132767 pubmed publisher
  32. Bikkavilli R, Avasarala S, Van Scoyk M, Arcaroli J, Brzezinski C, Zhang W, et al. Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer. Oncogene. 2015;34:5317-28 pubmed publisher
  33. Laurenti E, Frelin C, Xie S, Ferrari R, Dunant C, Zandi S, et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell. 2015;16:302-13 pubmed publisher
  34. Su C, Zhang C, Tecle A, Fu X, He J, Song J, et al. Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G1/S phase transition, acting as a co-activator of E2F-1 in cell cycle regulation. J Biol Chem. 2015;290:7208-20 pubmed publisher
  35. Dumitrescu A, Aberdeen G, Pepe G, Albrecht E. Placental estrogen suppresses cyclin D1 expression in the nonhuman primate fetal adrenal cortex. Endocrinology. 2014;155:4774-84 pubmed publisher
  36. Zhang K, Dai L, Zhang B, Xu X, Shi J, Fu L, et al. miR-203 is a direct transcriptional target of E2F1 and causes G1 arrest in esophageal cancer cells. J Cell Physiol. 2015;230:903-10 pubmed publisher
  37. Wang Y, Zhou D, Chen S. SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1. Mol Endocrinol. 2014;28:935-48 pubmed publisher
  38. van der Linden M, Willekes M, van Roon E, Seslija L, Schneider P, Pieters R, et al. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL. Cell Cycle. 2014;13:834-44 pubmed publisher
  39. Malaviya A, Sylvester P. Synergistic Antiproliferative Effects of Combined ? -Tocotrienol and PPAR ? Antagonist Treatment Are Mediated through PPAR ? -Independent Mechanisms in Breast Cancer Cells. PPAR Res. 2014;2014:439146 pubmed publisher
  40. Yang G, Chang B, Yang F, Guo X, Cai K, Xiao X, et al. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 2010;16:3171-81 pubmed publisher